While LDHC silencing greatly reduced the cell survival of basal-like breast cancer cells via the downregulation of STAT3 signaling, it exerted the opposite effect in Her2-enriched breast cancer cells, which could be reversed by STAT3 inhibition. The gene discussed is ERBB2; the disease is breast cancer.